Although we cannot discard the DC-IL-10+-independent effects on the efficacy of gemcitabine in our combination protocols, the enhanced immunogenicity in tumor-free mice and the use of tumor models with poor presence of MDSC suggest a relevant mechanism through inhibition of moDC generation. This evidence concerns the gene IL10 and neoplasm.